Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Amgen Inc. AMGN stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Amgen has a trailing twelve months PE ratio of 13.79, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.37. If we focus on the stock’s long-term PE trend, the current level puts Amgen’s current PE ratio below its midpoint over the past five years, with the number having trended roughly downwards over the past few months.
Further, the stock’s PE also compares favorably with the Zacks classified Medical - Biomedical and Genetic sector’s trailing twelve months PE ratio, which stands at 32.26. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Amgen has a forward PE ratio (price relative to this year’s earnings) of just 13.35, so it is fair to say that a slightly more value-oriented path may be ahead for Amgen stock in the near term too.
While earnings are certainly important, it is essential to know how much you are paying for the growth of earnings as well. One can easily do that with the PEG ratio (ratio of the P/E to the expected future earnings growth rate).The PEG ratio gives a more complete picture of the valuation of a stock than the P/E ratio.
Amgen’s PEG ratio stands at just 2.18, compared with the Zacks Medical - Biomedical and Genetics average of 2.75. This suggests a decent undervalued trading relative to its earnings growth potential right now.
Broad Value Outlook
In aggregate, Amgen currently has a Zacks Value Style Score of ‘B’, putting it into the top 40% of all stocks we cover from this look. This makes Amgen a solid choice for value investors.
What About the Stock Overall?
Though Amgen might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘C’ and a Momentum score of ‘F’. This gives AMGN a Zacks VGM score—or its overarching fundamental grade—of ‘C’. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen two estimates go higher in the past sixty days compared to five lower, while the full year estimate has seen eight up and five down in the same time period.
This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has inched down by almost 1% in the past two months, while the full year estimate has inched upper by 0.9%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Amgen Inc. Price and Consensus
Amgen Inc. Price and Consensus | Amgen Inc. Quote
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
Amgen is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among Bottom 36% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, over the past two years, the Zacks Medical - Biomedical and Genetics industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Click for Free Amgen Inc. (AMGN) Stock Analysis Report >>
To read this article on Zacks.com click here.
Zacks Investment Research